|Wednesday, 13 September 2017, 13:25 HKT/SGT|
|The Answer to Viruses and Bacteria in the Home! Eliminates Viruses & Bacteria, Antimicrobial Action that Lasts for 1 Week |
TOKYO, Sept 13, 2017 - (JCN Newswire) - Eisai Co., Ltd. will launch Etak Antimicrobial Spray Alpha (classified as miscellaneous goods), which contains long-acting antimicrobial agent Etak, on September 19 (Tuesday). This product eliminates viruses and bacteria with an antimicrobial action that lasts for one week.
Etak, the main ingredient used in the product, is a long-acting antimicrobial agent developed by Professor Hiroki Nikawa of the Department of Oral Health Engineering at Hiroshima University's Graduate School of Biomedical and Health Sciences. An adhesive component in Etak chemically binds the antimicrobial component to the spray area, providing an antimicrobial effect that lasts for one week.
In the home, there are many surfaces and items, such as doorknobs, bannisters, tables, flooring, and toys, to which viruses and bacteria can spread easily when touched. This product is an answer to the needs of consumers who wish to keep those viruses and bacteria at bay. We suggest habitually using Etak Antimicrobial Spray Alpha to eliminate viruses and bacteria in the home. Additionally, this product contains no alcohol and is both scentless and colorless, making it ideal for use on a wide variety of surfaces and items in the home.
Eisai is also marketing Etak Antimicrobial Spray, an alcohol type spray for mouth masks which uses the same long-acting antimicrobial agent Etak. By spraying it on a mouth mask prior to use, you can prevent viruses and bacteria from collecting on the mask for 24 hours.
Eisai remains committed to ensuring the delivery of products that satisfy the diversified needs of consumers and to making further contributions to increase the benefits provided to them.
1. Product Name: Etak Antimicrobial Spray Alpha (Miscellaneous Goods)
2. Ingredients: Water, long-acting antimicrobial agent (compound containing ethoxysilane), solubilizing agent, stabilizing agent
3. Directions for use:
- Please remove stopper when using. Returning the stopper locks the product.
- Please keep the nozzle 20-30cm away from the target and spray an appropriate amount.
- When using for the first time, please press the spray button a few times to activate the spray mechanism.
- In order to achieve a uniform spread, please wipe the surface with a cloth or other item after spraying.
- Please do not use this product upside down.
4. Volume / Suggested retail price (excluding tax): 250ml / 1,280 yen
5. Manufacturer: Jex Co., Ltd.
6. Supplier: Eisai Co., Ltd.
About long-acting antimicrobial agent Etak
Etak was developed by Professor Hiroki Nikawa of the Department of Oral Health Engineering at Hiroshima University's Graduate School of Biomedical and Health Sciences. It is a patented longacting antimicrobial agent (patent number: 4830075) that combines quaternary ammonium salts, which are also included in hand sanitizers and oral cleansing agents used by dentists, with a silane analogue, an immobilizing agent that functions as adhesive. When a quaternary ammonium salt is sprayed onto an object, it would normally lose its antimicrobial properties upon drying. However, with Etak, the adhesive component chemically binds the antimicrobial component to the spray area, thereby preserving the antimicrobial effect.
Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Public Relations Department,
Eisai Co., Ltd.
Sept 13, 2017 13:25 HKT/SGT
Eisai (TSE: 4523)
Topic: Press release summary
From the Asia Corporate News Network
Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|June 14, 2018 09:11 HKT/SGT|
Eisai: Industry-Academia-Government Joint Development Agreement Concerning Nucleic Acid Drug Discovery Research|
|June 13, 2018 11:53 HKT/SGT|
Eisai to Establish New Research Facility "Eisai Center for Genetics Guided Dementia Discovery" in Cambridge, Massachusetts, USA|
|June 11, 2018 11:44 HKT/SGT|
AbbVie and Eisai Announce the Launch of HUMIRA Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA|
|June 6, 2018 11:16 HKT/SGT|
Eisai: Positive New Data on Investigational Lemborexant Presented at 32nd Annual SLEEP Meeting|
|June 5, 2018 09:08 HKT/SGT|
Eisai: PhaseII Clinical Study of Elenbecestat Demonstrate Safety and Tolerability in MCI and Mild to Moderate Alzheimer's Disease at 18-Months|
|June 4, 2018 20:10 HKT/SGT|
Eisai and Merck Announce Data at 2018 ASCO Annual Meeting|
|May 31, 2018 12:33 HKT/SGT|
U.S. FDA Designates for Priority Review of Eisai's Supplemental New Drug Application for Antiepileptic Drug Fycoma|
|May 28, 2018 16:06 HKT/SGT|
Eisai: PIII Clinical Study Data on Chronic Constipation Treatment "GOOFICE 5mg Tablet" will be Presented at DDW2018|
|May 25, 2018 14:00 HKT/SGT|
Eisai: Potent New Mechanism of Action for Treatment of Inflammatory Bowel Disease |
|May 25, 2018 10:43 HKT/SGT|
Eisai and Merck & Co. Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib|
|More news >>|